A clinical trial in patients with obesity and DM showed that chronic administration of a long-acting form of FGF21 caused a marked elevation of circulating adiponectin levels and an obvious reduction in blood levels of total and LDL-cholesterol [7]. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.